TG THERAPEUTICS, INC. 10-K

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. Market Information Our common stock is listed on the Nasdaq Capital Market and trades under the symbol “TGTX”. Holders The number of record holders of our common stock as of February 17, 2023 was 218. Dividends We have never declared or paid any cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors. Securities Authorized for Issuance Under Equity Compensation Plans The following table provides information as of December 31, 2022, regarding the securities authorized for issuance under our equity compensation plans, the TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (the 2012 Incentive Plan) and the TG Therapeutics, Inc. 2022 Incentive Plan (the 2022 Incentive Plan). There were no additional shares available to be issued under the 2012 Incentive Plan. 66 Table of Contents Equity Compensation Plan Information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ ​ ​ ​ ​ ​ securities ​ ​ ​ ​ ​ ​ remaining ​ ​ ​ ​ ​ ​ available for ​ ​ Number of ​ ​ ​ future issuance ​ ​ securities to be ​ ​ ​ under equity ​ ​ issued upon ​ Weighted-average ​ compensation ​ ​ exercise of ​ exercise price of ​ plans (excluding ​ ​ outstanding ​ outstanding ​ securities reflected Plan Category ​ options ​ options ​ in column 1) ​ ​ ​ ​ ​ ​ ​ ​ Equity compensation plans approved by security holders ​ 5,135,685 ​ $ 7.10 ​ 12,251,485 Equity compensation plans not approved by security holders ​ — ​ ​ — ​ — Total ​ 5,135,685 ​ $ 7.10 ​ 12,251,485 ​ For information about all of our equity compensation plans see Note 5 to our Consolidated Financial Statements included in this report. COMMON STOCK PERFORMANCE GRAPH The following graph compares the cumulative total stockholder return on our common stock for the period from December 31, 2017 through December 31, 2022, with the cumulative total return over such period on (i) the U.S. Index of The Nasdaq Stock Market and (ii) the Biotechnology Index of The Nasdaq Stock Market. The graph assumes an investment of $100 on December 31, 2017, in our common stock (at the adjusted closing market price) and in each of the indices listed above, and assumes the reinvestment of all dividends. Measurement points are December 31 of each year. * $100 invested on December 31, 2017 in stock or index, including reinvestment of dividends. Fiscal Years ending December 31. ITEM 6. REMOVED AND RESERVED ​ ​ 67 Table of Contents